Fecal Adnab-9 binding as a risk marker for colorectal neoplasia
- PMID: 15893419
- DOI: 10.1016/j.canlet.2005.03.042
Fecal Adnab-9 binding as a risk marker for colorectal neoplasia
Abstract
Adnab-9 binding in colonic tissue and effluent has been associated with an increased risk for colorectal neoplasia. We investigated if fecal binding by Adnab-9 may be used as a marker for colorectal neoplasia. A fecal-Adnab-9 ELISA was performed on samples of 249 patients and colonoscopic pathology results correlated. Fecal Adnab-9 binding was seen in 63% of patients with colorectal neoplasia (59% with colorectal cancer and 83% with adenoma), 33% with inflammatory bowel disease, 0% with hyperplastic polyps and 10% of controls. We conclude that fecal Adnab-9 binding is a promising risk marker for colorectal neoplasia.
Similar articles
-
Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.Anticancer Res. 2003 Mar-Apr;23(2A):851-3. Anticancer Res. 2003. PMID: 12820312
-
Fecal lysozyme: an unreliable marker for colorectal cancer.Am J Gastroenterol. 1992 May;87(5):617-21. Am J Gastroenterol. 1992. PMID: 1595650
-
Detection of gastric cancer and premalignant lesions by novel marker glycoprotein 87 using monoclonal antibody Adnab-9.Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1095-9. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 14578149
-
New stool screening tests for colorectal cancer.Digestion. 2007;76(1):26-33. doi: 10.1159/000108391. Epub 2007 Oct 19. Digestion. 2007. PMID: 17947816 Review.
-
[Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data].Z Gastroenterol. 2005 Dec;43(12):1313-7. doi: 10.1055/s-2005-858657. Z Gastroenterol. 2005. PMID: 16315127 Review. German.
Cited by
-
The Non-Invasive Prediction of Colorectal Neoplasia (NIPCON) Study 1995-2022: A Comparison of Guaiac-Based Fecal Occult Blood Test (FOBT) and an Anti-Adenoma Antibody, Adnab-9.Int J Mol Sci. 2023 Dec 8;24(24):17257. doi: 10.3390/ijms242417257. Int J Mol Sci. 2023. PMID: 38139086 Free PMC article.
-
The Innate Immune System Surveillance Biomarker p87 in African Americans and Caucasians with Small High-Grade Dysplastic Adenoma [SHiGDA] and Right-Sided JAK3 Colon Mutations May Explain the Presence of Multiple Cancers Revealing an Important Minority of Patients with JAK3 Mutations and Colorectal Neoplasia.Gastrointest Disord (Basel). 2024 Jun 7;6(2):497-512. doi: 10.3390/gidisord6020034. Gastrointest Disord (Basel). 2024. PMID: 39507544 Free PMC article.
-
Prospective markers for early diagnosis and prognosis of sporadic pancreatic ductal adenocarcinoma.Dig Dis Sci. 2013 Mar;58(3):744-50. doi: 10.1007/s10620-012-2387-x. Epub 2012 Sep 22. Dig Dis Sci. 2013. PMID: 23001406
-
Screening tests for colorectal cancer: a menu of options remains relevant.Curr Oncol Rep. 2006 Nov;8(6):492-8. doi: 10.1007/s11912-006-0079-4. Curr Oncol Rep. 2006. PMID: 17040627 Review.
-
Helicobacter pylori Status May Differentiate Two Distinct Pathways of Gastric Adenocarcinoma Carcinogenesis.Curr Oncol. 2023 Aug 29;30(9):7950-7963. doi: 10.3390/curroncol30090578. Curr Oncol. 2023. PMID: 37754493 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical